Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. doi: 10.1128/AAC.00470-19. Print 2019 Jun.

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Author information

1
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
3
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA enuermb@jhmi.edu.

Abstract

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

KEYWORDS:

Mycobacterium abscessus ; drug susceptibility assay; eravacycline; omadacycline; tetracyclines; tigecycline

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center